Literature DB >> 27070052

Safety concerns with long-term opioid use.

Michael Harned1, Paul Sloan1.   

Abstract

INTRODUCTION: The benefits of opioid therapy must be balanced by any adverse effects. In recent years, prescription opioids have been increasingly prescribed, but have also been associated with increased abuse, overdose and death. AREAS COVERED: This review will categorize the common risks of opioid administration. Recognized adverse effects of opioid therapy include constipation, tolerance, endocrinopathies, sleep disorders, cognitive effects, respiratory depression, overdose and addiction. Studies have shown that there is increased risk of overdose and death with higher daily opioid doses, particularly above a morphine equivalent oral daily dose of 100 milligrams. Extended-release/long acting (ER/LA) opioid formulations may be beneficial for the compliant patient, yet may expose a higher risk for abuse if used inappropriately since each tablet carries a larger dose of medication. EXPERT OPINION: Prospective, controlled one-year trials are needed to establish the efficacy and safety profile of chronic opioid therapy. In addition to the well known side effects of chronic opioid therapy, the influence and serious effect of opioids on sleep and central sleep apnea is only recently being investigated. The lowest possible daily opioid must be used to manage chronic pain, and all clinicians should be cautious in the use of daily morphine equivalent doses above 50-100 milligrams.

Entities:  

Keywords:  Chronic pain; abuse deterrence; extended-release; naloxone; naltrexone; opioids

Mesh:

Substances:

Year:  2016        PMID: 27070052     DOI: 10.1080/14740338.2016.1177509

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  8 in total

1.  Medical Use of Long-term Extended-release Opioid Analgesics in Commercially Insured Adults in the United States.

Authors:  Jessica C Young; Michele Jonsson Funk; Nabarun Dasgupta
Journal:  Pain Med       Date:  2020-04-01       Impact factor: 3.750

2.  Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists.

Authors:  Shaness A Grenald; Madison A Young; Yue Wang; Michael H Ossipov; Mohab M Ibrahim; Tally M Largent-Milnes; Todd W Vanderah
Journal:  Neuropharmacology       Date:  2016-12-20       Impact factor: 5.250

3.  Prescribing Trends of Codeine-containing Medications and Other Opioids in Primary Care After A Regulatory Decision: An Interrupted Time Series Analysis.

Authors:  Niccolò Lombardi; Alfredo Vannacci; Alessandra Bettiol; Ettore Marconi; Serena Pecchioli; Alberto Magni; Claudio Cricelli; Francesco Lapi
Journal:  Clin Drug Investig       Date:  2019-05       Impact factor: 2.859

4.  The gut microbiota mediates reward and sensory responses associated with regimen-selective morphine dependence.

Authors:  Kevin Lee; Helen E Vuong; David J Nusbaum; Elaine Y Hsiao; Christopher J Evans; Anna M W Taylor
Journal:  Neuropsychopharmacology       Date:  2018-09-10       Impact factor: 7.853

5.  Viral Vector-Mediated Gene Transfer of Glutamic Acid Decarboxylase for Chronic Pain Treatment: A Literature Review.

Authors:  Megumi Kanao-Kanda; Hirotsugu Kanda; Shue Liu; Sabita Roy; Michal Toborek; Shuanglin Hao
Journal:  Hum Gene Ther       Date:  2020-03-24       Impact factor: 5.695

6.  Pilot survey of prescription opioid use patterns and engagement with harm-reduction strategies in emergency department patients.

Authors:  Lindsay M Fox; Siri Shastry; Avis Harper-Brooks; Christine Ramdin; Alex F Manini
Journal:  Explor Res Clin Soc Pharm       Date:  2021-08-17

7.  Morphine dependence is attenuated by red ginseng extract and ginsenosides Rh2, Rg3, and compound K.

Authors:  Taddesse Yayeh; Kyunghwa Yun; Soyong Jang; Seikwan Oh
Journal:  J Ginseng Res       Date:  2016-08-21       Impact factor: 6.060

8.  Comprehensive pain management as a frontline treatment to address the opioid crisis.

Authors:  Joseph Gregory Hobelmann; Andrew S Huhn
Journal:  Brain Behav       Date:  2021-09-23       Impact factor: 2.708

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.